Exosomes Pipeline Insight

DelveInsight’s, “Exosomes Pipeline Insight, 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Exosomes Understanding

Exosomes Overview

Exosomes are small extracellular vesicles (≈40–160 nm) released by most cell types through the fusion of multivesicular bodies with the plasma membrane, which liberates intraluminal vesicles into the extracellular space. They are widely present in biological fluids such as blood, urine, breast milk, and semen, and can be taken up by distant cells. Through the transfer of bioactive cargo, exosomes play a crucial role in cell–cell communication and can influence disease progression. Their contents including proteins, lipids, nucleic acids, amino acids, and metabolites reflect their cell of origin and are shaped during their biogenesis in the endosomal pathway. Owing to these properties, exosomes are being actively explored for diagnostic and therapeutic applications, particularly in drug discovery. They are commonly isolated using techniques such as differential centrifugation and polymer-based precipitation.

Exosomes are formed through a double invagination process of the plasma membrane, leading to the creation of multivesicular bodies (MVBs) that contain intraluminal vesicles (ILVs), which are later released as exosomes (~40–160 nm) upon fusion with the plasma membrane. Their biogenesis begins with the formation of early-sorting endosomes that mature into late endosomes and eventually MVBs, incorporating cellular components from sources like the endoplasmic reticulum and Golgi apparatus. This process is tightly regulated by proteins such as ESCRT complexes, Rab GTPases, ALIX, and tetraspanins, which facilitate cargo sorting, membrane budding, and vesicle release via ESCRT-dependent and independent pathways. Exosomes carry diverse biomolecules including DNA, RNA, proteins, lipids, and metabolites reflecting their cell of origin and functional state. They are secreted by a wide range of cell types into various body fluids through constitutive or inducible pathways, the latter being influenced by stressors such as pathogens or drugs.

Exosomes are being widely investigated for both diagnostic and therapeutic applications due to their complex molecular cargo and natural role in intercellular communication. As they are present in nearly all biological fluids, they offer a minimally invasive “liquid biopsy” approach for disease detection and monitoring across conditions such as cancer, cardiovascular, neurological, and organ-specific diseases. Therapeutically, exosomes exhibit excellent biocompatibility, low immunogenicity, and efficient biodistribution, enabling targeted delivery of functional biomolecules to diseased cells. They can also serve as natural drug delivery vehicles, capable of crossing biological barriers like the blood–brain barrier and delivering payloads such as RNA or drugs with reduced toxicity. Emerging strategies including engineered drug-loaded exosomes and CAR-derived exosomes highlight their promise in advanced treatments, particularly in oncology. 

"Exosomes Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the drug class. A detailed picture of the Exosomes pipeline landscape is provided which includes the overview and Exosomes applications. The assessment part of the report embraces, in depth Exosomes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Exosomes pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Exosomes Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches to treat/improve Exosomes.

Exosomes Emerging Drugs Analysis

This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs

CAP-1002: Capricor Therapeutics

Capricor’s CAP-1002 consists of cardiosphere-derived cells (CDCs), a type of cardiac progenitor cell originally discovered in the laboratory of its scientific founder, Eduardo Marbán. These CDCs have been extensively studied, with over 100 peer-reviewed publications and clinical administration in more than 200 patients across multiple trials. CAP-1002 works by releasing exosomes, small vesicles that influence immune responses and promote tissue repair. These exosomes are primarily taken up by macrophages and T cells, triggering regenerative processes and modulating immune activity. The therapy is currently in the registration stage for the treatment of Duchenne Muscular Dystrophy.

Debamestrocel: BrainStorm Cell Therapeutics

Debamestrocel (NurOwn) consists of autologous bone marrow–derived mesenchymal stem cells (MSCs) that are cultured to secrete elevated levels of neurotrophic factors, supporting neuronal survival and repair. These MSC-NTF cells combine the immunomodulatory effects of MSCs with enhanced neurotrophic activity, partly mediated through exosome-based delivery of factors such as GDNF. The therapy is manufactured from a patient’s own MSCs, expanded and differentiated ex vivo without genetic modification, and then re-administered. It is currently in Phase III development for the treatment of Amyotrophic Lateral Sclerosis, with additional programs in multiple neurological disorders at earlier stages.

AGLE-102: Aegle Therapeutics

AGLE-102 is an allogeneic extracellular vesicle (EV) therapy derived from mesenchymal stem cells obtained from healthy donors. It consists of MSC-derived vesicles that deliver proteins, genetic material, and regenerative factors to support repair in damaged tissues. The therapy is currently in Phase I/II development for the treatment of burns and Epidermolysis Bullosa Dystrophica, and is also being explored at the preclinical stage for Graft-versus-Host Disease.

RioMSK001: RION

RioMSK001 is an innovative therapeutic candidate developed by Rion for musculoskeletal disorders. It is designed to address degenerative joint conditions with a focus on improving function and reducing disease burden. According to the company’s pipeline, the therapy is currently in early clinical evaluation. It is in Phase I development for the treatment of Knee Osteoarthritis.

HEPATOSOME: ExoStemTech

HEPATOSOME is an investigational therapy being developed by ExoStemTech. It is designed as a novel approach targeting liver-related disorders through advanced therapeutic mechanisms. The candidate is currently undergoing early-stage research and evaluation. At present, it is in preclinical development for the treatment of Liver Fibrosis.

Further product details are provided in the report……..

Exosomes Drug Therapeutic Assessment

This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:

Major Exosomes Players in Exosomes

There are approx. 100+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. Registration include, Capricor Therapeutics.

Exosomes Clinical Trial Phases Phases

DelveInsight’s report covers around 110+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Exosomes Drug Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Exosomes Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Exosomes Clinical Trial Activities

The Exosomes Pipeline report provides insights into different Exosomes Clinical Trials  within Phase III, II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs. 

Exosomes Pipeline Development Activities

The Exosomes clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Exosomes Pipeline Report Insights

• Exosomes Pipeline Analysis
• Exosomes Therapeutic Assessment
• Exosomes Unmet Needs
• Impact of Exosomes Drugs

Exosomes Pipeline Report Assessment

• Exosomes Pipeline Product Profiles
• Exosomes Therapeutic Assessment
• Exosomes Pipeline Assessment
• Exosomes Inactive drugs assessment
• Exosomes Market Unmet Needs

Discover actionable insights into the Exosomes market trends, epidemiology trends, and forecast through 2034 to stay ahead in emerging therapies.

Key Questions Answered In The Exosomes Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Exosomes drugs?
• How many Exosomes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Exosomes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Exosomes and their status?
• What are the key designations that have been granted to the emerging drugs?

Exosomes Key Companies

• Capricor Therapeutics
• BrainStorm Cell Therapeutics
• Aegle Therapeutics
• EXO Biologics
• RION
• S&E bio
• Shine-On Biomedical Co., Ltd.
• ImmVira
• ILIAS Biologics
• Secretome Therapeutics
• VesiCURE Therapeutics
• Everzom
• Brexogen
• ShiftBio
• Conveyxo
• Exogenus Therapeutics
• Coya Therapeutics
• VivaZome Therapeutics
• NurExone
• Ji Yan Biomedical Co., Ltd.

Exosomes Key Products

• CAP-1002
• Debamestrocel
• AGLE-102
• EXOB-001
• RioMSK001
• SNE-101
• SOB 100
• MVR-EX101
• ILB 202
• STM-01
• MDX-101
• EViv
• BRE-NA01
• SBI-101
• EXOSTEO01
• Exo–101
• COYA 201
• VZT-PEV
• ExoPTEN therapy
• ExoVeris

Explore comprehensive insights into Exosomes epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.